195 related articles for article (PubMed ID: 35896267)
1. Extracellular Vesicles from
Janpipatkul K; Panvongsa W; Worakitchanon W; Reungwetwattana T; Chairoungdua A
Anticancer Res; 2022 Aug; 42(8):3835-3844. PubMed ID: 35896267
[TBL] [Abstract][Full Text] [Related]
2. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH
Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820
[TBL] [Abstract][Full Text] [Related]
3. Osimertinib Induces the Opposite Effect of Proliferation and Migration in the Drug Resistance of EGFR-T790M Non-small Cell Lung Cancer Cells.
Wang RH; Chang CJ; Chen CH; Liu KK; Chao JI
Anticancer Agents Med Chem; 2023; 23(11):1309-1319. PubMed ID: 36815658
[TBL] [Abstract][Full Text] [Related]
4. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
6. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
7. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
[TBL] [Abstract][Full Text] [Related]
8. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
9. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
10. Effects of Ephedra Herb extract on the expression of EGFR-activating mutations and c-Met in non-small-cell lung cancer cell line, H1975, and its combined effects with osimertinib.
Mori E; Hyuga S; Hanawa T; Naoki K; Odaguchi H
J Nat Med; 2023 Jun; 77(3):523-534. PubMed ID: 37043119
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR).
Fawwaz M; Mishiro K; Nishii R; Sawazaki I; Shiba K; Kinuya S; Ogawa K
Molecules; 2020 Jun; 25(12):. PubMed ID: 32599930
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827-TR.
Yu T; Xia Q; Gong T; Wang J; Zhong D
Thorac Cancer; 2020 May; 11(5):1129-1138. PubMed ID: 32163227
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
[TBL] [Abstract][Full Text] [Related]
14. Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation.
Lian Z; Du W; Zhang Y; Fu Y; Liu T; Wang A; Cai T; Zhu J; Zeng Y; Liu Z; Huang JA
Thorac Cancer; 2020 Jul; 11(7):1934-1943. PubMed ID: 32433828
[TBL] [Abstract][Full Text] [Related]
15. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.
Kook E; Lee J; Kim DH
Arch Toxicol; 2024 May; 98(5):1437-1455. PubMed ID: 38443724
[TBL] [Abstract][Full Text] [Related]
16. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and preclinical evaluation of two osimertinib isotopologues labeled with carbon-11 as PET tracers targeting the tyrosine kinase domain of the epidermal growth factor receptor.
Högnäsbacka A; Poot AJ; Kooijman E; Schuit RC; Schreurs M; Verlaan M; van den Hoek J; Heideman DAM; Beaino W; van Dongen GAMS; Vugts DJ; Windhorst AD
Nucl Med Biol; 2023; 120-121():108349. PubMed ID: 37209556
[TBL] [Abstract][Full Text] [Related]
18. Nanoplasmonic Detection of EGFR Mutations Based on Extracellular Vesicle-Derived EGFR-Drug Interaction.
Han J; Jung JH; Lee SY; Park JH
ACS Appl Mater Interfaces; 2024 Feb; 16(7):8266-8274. PubMed ID: 38335730
[TBL] [Abstract][Full Text] [Related]
19. [Ionizing Radiation Reduces TKI Resistance Caused by T790M Mutation in NSCLC Cell Lines].
Li J; Wu X; Wang Z; Shen Z; Sun N; Zhu X
Zhongguo Fei Ai Za Zhi; 2015 Aug; 18(8):475-80. PubMed ID: 26302343
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
